Exelixis (EXEL) revenue breakdown

Healthcare · Biotechnology · Market cap $14.3B

By product, Net product revenues is the largest at 91% of fiscal 2025 revenue, growing 36% a year over 9 years.

By region, U.S. is the largest at 92% of fiscal 2025 revenue, growing 35% a year over 9 years.

Revenue by product

Fiscal years, as Exelixis reports them in its 10-K filings; fiscal 2025 total $2.3B.

Products2016201720182019202020212022202320242025Share
Net product revenues$135M$349M$619M$760M$742M$1.1B$1.4B$1.6B$1.8B$2.1B 91%
Collaboration services revenues——$34M$42M$79M$108M$48M$201M$359M$197M 9%
License revenues——$200M$166M$167M$250M$162M——— —
Collaboration revenues$56M$103M———————— —

Revenue by region

Fiscal years, as Exelixis reports them in its 10-K filings; fiscal 2025 total $2.3B.

Regions2016201720182019202020212022202320242025Share
U.S.$141M$368M$633M$770M$753M$1.1B$1.4B$1.6B$1.8B$2.1B 92%
Europe$36M$70M$183M$153M$152M$302M$169M$145M$319M$154M 7%
Japan$15M$15M$38M$45M$83M$44M$29M$39M$27M$26M 1%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EXEL.
Open EXEL in Investingly

Questions

Where does Exelixis make its money?

In fiscal 2025, by product: Net product revenues $2.1B, Collaboration services revenues $197M.

From Exelixis's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.